{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-093684","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.151697+00:00","generated_at":"2026-06-11T06:33:12.338071+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Apogee Therapeutics appoints Mark C. McKenna as Chairman of Board","bullets":["Mark C. McKenna appointed as Chairman and Class III director, effective August 17, 2023.","Former President, CEO, and Chairman of Prometheus Biosciences, acquired by Merck for ~$10.8B.","Previously President of Salix Pharmaceuticals and senior roles at Bausch + Lomb and Johnson & Johnson.","Annual compensation of $84,000 for Chair and committee roles; options for 50,000+100,000 shares vesting over 3 years.","McKenna holds B.S. from Arizona State and MBA from Azusa Pacific; brings I&I development and commercial expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-093684","json":"https://secwatch.observer/filing/0001104659-23-093684.json","markdown":"https://secwatch.observer/filing/0001104659-23-093684.md","text":"https://secwatch.observer/filing/0001104659-23-093684.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/0001104659-23-093684-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/tm2324210d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:33:12.338071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a04aa8c79","claim":"Mark C. McKenna was appointed as Chair of the Board at Apogee Therapeutics, Inc..","evidence_excerpt":"On August 17, 2023, the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) appointed Mark C. McKenna as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/0001104659-23-093684-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}